Research Summary

I have trained more than 100 postdoctoral fellows and visiting scientists during my career, most of whom currently hold faculty positions at various academic institutions. I have published over 350 research manuscripts in peer-reviewed journals. I completed my postdoctoral fellowship in Oncology and Molecular Biology from the University of Chicago Pritzker School of Medicine. I joined University of California San Francisco School of Medicine (UCSF) in 1987. I am currently a Professor and Director of Urology Research Center at UCSF/VAMC and a Senior Research Career Scientist (Department of Veterans Affairs, Washington DC) at the Veterans Affairs Health Care System, San Francisco. My research projects are funded through the VA and NIH and focused on investigating the following areas: (1) The role of non-coding RNAs in the initiation, progression and metastasis of urological cancers using in vitro and in vivo models. (2) Genetic biomarkers for diagnosis and prognosis of urological malignancies using clinical specimens. (3) Molecular mechanism of prostate cancer health disparities. (4) Mechanisms of drug resistance and its reversal using various pathways in vitro and in vivo models. (5) Role of dietary compounds for treatment and prevention of urological malignancies.

Research Funding

  • October 1, 2018 - September 30, 2025 - BLR&D Research Career Scientist Award Application, Principal Investigator. Sponsor: VA, Sponsor Award ID: IK6BX004473
  • June 1, 2016 - May 31, 2021 - Molecular biomarkers for kidney cancer prognosis using non-coding RNAs, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R01CA199694
  • October 1, 2011 - September 30, 2020 - Regulation of c-Myc/HIF pathway in the management of kidney cancer, Principal Investigator. Sponsor: VA, Sponsor Award ID: I01BX001123
  • July 1, 2015 - June 30, 2020 - Genetic factors for race related prostate cancer., Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: U01CA184966


Kurukshetra University, India, MS, 1978, Biochemistry
Postgraduate Institute of Medical Education and Research, Chandigarh, India, PhD, 1982, Biochemistry
University of Chicago, Chicago, IL, Post-Doc, 1983-1987, Biochemistry

Honors & Awards

  • 2006-2013
    Associate Editor, Cancer Research
  • 2013-present
    Associate Editor Clinical Cancer Research
  • 2011-present
    Academic Editor, PLoS ONE
  • 2011-present
    Senior Editor, Amer. J. Cancer Res.

Selected Publications

  1. Kulkarni P, Dasgupta P, Hashimoto Y, Shiina M, Shahryari V, Tabatabai ZL, Yamamura S, Tanaka Y, Saini S, Dahiya R, Majid S A lncRNA TCL6-miRNA-155 interaction regulates the Src-Akt-EMT network to mediate kidney cancer progression and metastasis.  View on PubMed
  2. Kulkarni P, Dasgupta P, Bhat NS, Hashimoto Y, Saini S, Shahryari V, Yamamura S, Shiina M, Tanaka Y, Dahiya R, Majid S Role of the PI3K/Akt pathway in cadmium induced malignant transformation of normal prostate epithelial cells.  View on PubMed
  3. Bhagirath D, Liston M, Patel N, Akoto T, Lui B, Yang TL, To DM, Majid S, Dahiya R, Tabatabai ZL, Saini S MicroRNA determinants of neuroendocrine differentiation in metastatic castration-resistant prostate cancer.  View on PubMed
  4. Dasgupta P, Kulkarni P, Majid S, Hashimoto Y, Shiina M, Shahryari V, Bhat NS, Tabatabai L, Yamamura S, Saini S, Tanaka Y, Dahiya R LncRNA CDKN2B-AS1/miR-141/cyclin D network regulates tumor progression and metastasis of renal cell carcinoma.  View on PubMed
  5. Dasgupta P, Kulkarni P, Bhat NS, Majid S, Shiina M, Shahryari V, Yamamura S, Tanaka Y, Gupta RK, Dahiya R, Hashimoto Y Activation of the Erk/MAPK signaling pathway is a driver for cadmium induced prostate cancer.  View on PubMed
  6. Imai-Sumida M, Dasgupta P, Kulkarni P, Shiina M, Hashimoto Y, Shahryari V, Majid S, Tanaka Y, Dahiya R, Yamamura S Genistein Represses HOTAIR/Chromatin Remodeling Pathways to Suppress Kidney Cancer.  View on PubMed
  7. Bhagirath D, Dahiya R, Majid S, Tabatabai ZL, Saini S Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients.  View on PubMed
  8. Bhagirath D, Yang TL, Tabatabai ZL, Majid S, Dahiya R, Tanaka Y, Saini S BRN4 Is a Novel Driver of Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer and Is Selectively Released in Extracellular Vesicles with BRN2.  View on PubMed
  9. Cagle P, Niture S, Srivastava A, Ramalinga M, Aqeel R, Rios-Colon L, Chimeh U, Suy S, Collins SP, Dahiya R, Kumar D MicroRNA-214 targets PTK6 to inhibit tumorigenic potential and increase drug sensitivity of prostate cancer cells.  View on PubMed
  10. Bhagirath D, Yang TL, Tabatabai ZL, Shahryari V, Majid S, Dahiya R, Tanaka Y, Saini S Role of a novel race-related tumor suppressor microRNA located in frequently deleted chromosomal locus 8p21 in prostate cancer progression.  View on PubMed
  11. Hashimoto Y, Shiina M, Dasgupta P, Kulkarni P, Kato T, Wong RK, Tanaka Y, Shahryari V, Maekawa S, Yamamura S, Saini S, Deng G, Tabatabai ZL, Majid S, Dahiya R Upregulation of miR-130b Contributes to Risk of Poor Prognosis and Racial Disparity in African-American Prostate Cancer.  View on PubMed
  12. Kido T, Li Y, Tanaka Y, Dahiya R, Chris Lau YF The X-linked tumor suppressor TSPX downregulates cancer-drivers/oncogenes in prostate cancer in a C-terminal acidic domain dependent manner.  View on PubMed
  13. Chang I, Mitsui Y, Kim SK, Sun JS, Jeon HS, Kang JY, Kang NJ, Fukuhara S, Gill A, Shahryari V, Tabatabai ZL, Greene KL, Dahiya R, Shin DM, Tanaka Y Correction: Cytochrome P450 1B1 inhibition suppresses tumorigenicity of prostate cancer via caspase-1 activation.  View on PubMed
  14. Kato T, Hashimoto Y, Wong RK, Mitsui Y, Maekawa S, Chang I, Shahryari V, Yamamura S, Majid S, Saini S, Tabatabai ZL, Dahiya R, Deguchi T, Tanaka Y Influence of lifestyle choices on risks of CYP1B1 polymorphisms for prostate cancer.  View on PubMed
  15. Kulkarni P, Dasgupta P, Bhat NS, Shahryari V, Shiina M, Hashimoto Y, Majid S, Deng G, Saini S, Tabatabai ZL, Yamamura S, Tanaka Y, Dahiya R Elevated miR-182-5p Associates with Renal Cancer Cell Mitotic Arrest through Diminished MALAT-1 Expression.  View on PubMed
  16. Yamamoto Y, Tsunedomi R, Fujita Y, Otori T, Ohba M, Kawai Y, Hirata H, Matsumoto H, Haginaka J, Suzuki S, Dahiya R, Hamamoto Y, Matsuyama K, Hazama S, Nagano H, Matsuyama H Pharmacogenetics-based area-under-curve model can predict efficacy and adverse events from axitinib in individual patients with advanced renal cell carcinoma.  View on PubMed
  17. Dasgupta P, Kulkarni P, Majid S, Shahryari V, Hashimoto Y, Bhat NS, Shiina M, Deng G, Saini S, Tabatabai ZL, Yamamura S, Tanaka Y, Dahiya R MicroRNA-203 Inhibits Long Noncoding RNA HOTAIR and Regulates Tumorigenesis through Epithelial-to-mesenchymal Transition Pathway in Renal Cell Carcinoma.  View on PubMed
  18. Bhagirath D, Yang TL, Bucay N, Sekhon K, Majid S, Shahryari V, Dahiya R, Tanaka Y, Saini S microRNA-1246 Is an Exosomal Biomarker for Aggressive Prostate Cancer.  View on PubMed
  19. Bhagirath D, Yang TL, Dahiya R, Saini S MicroRNAs as Regulators of Prostate Cancer Metastasis.  View on PubMed
  20. Fujii N, Hirata H, Ueno K, Mori J, Oka S, Shimizu K, Kawai Y, Inoue R, Yamamoto Y, Matsumoto H, Shimabukuro T, Udoh K, Hoshii Y, Dahiya R, Matsuyama H Extracellular miR-224 as a prognostic marker for clear cell renal cell carcinoma.  View on PubMed

Go to UCSF Profiles, powered by CTSI